Checkpoint Blockade Immunotherapy Targets Tumor-Specific Mutant Antigens

Get Permission

In a study reported in Nature, Gubin and colleagues showed that the effects of CTLA-4 (cytotoxic T-lymphocyte–associated protein-4) and PD-1 PD-1 (programmed cell death protein-1) inhibitors (checkpoint blockade) are achieved through targeting of tumor-specific mutant antigens. In the study, genomic and bioinformatic approaches identified tumor-specific mutant proteins as a major class of T-cell rejection antigens following anti–PD-1 or anti–CTLA-4 treatment of mice with progressively growing sarcomas. Synthetic therapeutic long-peptide vaccines incorporating the mutant epitopes resulted in tumor rejection comparable to that observed with checkpoint blockade immunotherapy. It was observed that although mutant tumor antigen-specific T cells were present in progressively growing tumors, they were reactivated with anti–PD-1 or anti–CTLA-4 antibody treatment; the T cells displayed some overlapping transcriptional profiles but primarily expressed treatment-specific profiles that were associated with tumor rejection.

The investigators concluded: “These results reveal that tumor-specific mutant antigens are not only important targets of checkpoint blockade therapy, but they can also be used to develop personalized cancer-specific vaccines and to probe the mechanistic underpinnings of different checkpoint blockade treatments.” ■

Gubin MM, et al: Nature 515:577-581, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.